APA (7th ed.) Citation

M, S., A, F. C., H, Y., N, A., K, M., X, T., . . . SE, G. (2026). Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma. PharmacoEconomics, 44(5), 509. https://doi.org/10.1007/s40273-026-01591-7

Chicago Style (17th ed.) Citation

M, Scholte, et al. "Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma." PharmacoEconomics 44, no. 5 (2026): 509. https://doi.org/10.1007/s40273-026-01591-7.

MLA (9th ed.) Citation

M, Scholte, et al. "Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma." PharmacoEconomics, vol. 44, no. 5, 2026, p. 509, https://doi.org/10.1007/s40273-026-01591-7.